Menu Search
Equities

Irwin Naturals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
97X:FRA

Irwin Naturals Inc

Actions
  • Price (EUR)0.154
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 07 2024 07:14 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Irwin Naturals Inc. is a nutraceutical company. The Company is leveraging its brand into both the cannabis and psychedelic sectors. The Company manufactures vitamins and other health supplements. It also owns and operates mental health clinics and an advertising company specializing in ketamine clinics in the United States. Its national chain of psychedelic mental health clinics is called Irwin Naturals Emergence. Its vitamins and supplements include better sleep; brain, mood & stress; cleanse + detox; immune support; men's health; multi-vitamins; RED (nitric oxide boost); sexual health; testosterone boosters; weight management, and women's health. The Company's cannabidiol (CBD) products include CBD +Turmeric Extra Strength, CBD +Melatonin Gummies 15 mg, CBD Oils 250 mg (unflavored), CBD Balm 1000 mg (Arnica), CBD Balm 1000 mg (lemongrass), CBD Soft Gels 30 mg, and CBD +Power to Sleep. Its portfolio of products is available in more than 100,000 retail doors across North America.

  • Revenue in CAD (TTM)118.12m
  • Net income in CAD-26.34m
  • Incorporated1987
  • Employees111.00
  • Location
    Irwin Naturals Inc300 Corporate Pointe, Suite 550CULVER CITY 90230United StatesUSA
  • Phone+1 (604) 628-5616
  • Fax+1 (604) 628-5616
  • Websitehttps://ir.irwinnaturals.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.